Conversion to lanthanum carbonate monotherapy effectively controls serum phosphorus with a reduced tablet burden: A multicenter open-label study

BMC Nephrology

Volumn 12, Issue 1, 2011, Pages

  Vemuri, Nirupama ^a   Michelis, Michael F ^b   Matalon, Albert ^c  

^a Sierra View District Hospital   (United States)

^b LENOX HILL HOSPITAL   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LANTHANUM CARBONATE; PHOSPHORUS; LANTHANUM; PHOSPHATE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TRANSFORMATION; FEMALE; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; OPEN STUDY; PATIENT SATISFACTION; PHASE 4 CLINICAL TRIAL; PHOSPHATE BLOOD LEVEL; AGED; BLOOD; CHRONIC KIDNEY FAILURE; HEALTH PERSONNEL ATTITUDE; HYPERPHOSPHATEMIA; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PHYSICIAN; TABLET; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ATTITUDE OF HEALTH PERSONNEL; FEMALE; HUMANS; HYPERPHOSPHATEMIA; KIDNEY FAILURE, CHRONIC; LANTHANUM; MALE; MIDDLE AGED; PATIENT SATISFACTION; PHOSPHATES; PHOSPHORUS; PHYSICIANS; TABLETS; TREATMENT OUTCOME;

EID: 80053373744     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-12-49     Document Type: Article

References (18)

1. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM, J Am Soc Nephrol 2004 15 8 2208 2218 10.1097/01.ASN.0000133041.27682.A2 15284307 (Pubitemid 39031360)
2. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. National Kidney Foundation, Am J Kidney Dis 2003 42 4 suppl 3 1 201 14520607
3. Hemodialysis patients' noncompliance with oral medications. Curtin RB, Svarstad BL, Keller TH, ANNA J 1999 26 3 307 316 10633602
4. The meaning of medications: another look at compliance. Conrad P, Soc Sci Med 1985 20 1 29 37 10.1016/0277-9536(85)90308-9 3975668 (Pubitemid 15235565)
5. Intentional prescription nonadherence (noncompliance) by the elderly. Cooper JK, Love DW, Raffoul PR, J Am Geriatr Soc 1982 30 5 329 333 7077010 (Pubitemid 12071029)
6. Issues in patient adherence to healthcare regimens. Kasl S, J Human Stress 1975 1 2 5 17 1235118
7. Compliance in hemodialysis patients: a multivariate regression analysis. Morduchowicz G, Sulkes J, Aizic S, Gabbay U, Winkler J, Boner G, Nephron 1993 64 3 365 368 10.1159/000187355 8341381 (Pubitemid 23202842)
8. Medication noncompliance in patients with chronic disease: issues in dialysis and renal transplantation. Loghman-Adham M, Am J Manag Care 2003 9 2 155 171 12597603 (Pubitemid 36292404)
9. Phosphate binders, K/DOQI guidelines, and compliance: the unfortunate reality. Tomasello S, Dhupar S, Sherman RA, Dial Transplant 2004 33 236 240
10. Medication prescribing patterns in ambulatory haemodialysis patients: comparisons of USRDS to a large not-for-profit dialysis provider. Manley HJ, Garvin CG, Drayer DK, Reid GM, Bender WL, Neufeld TK, Hebbar S, Muther RS, Nephrol Dial Transplant 2004 19 7 1842 1848 10.1093/ndt/gfh280 15128886 (Pubitemid 38961397)
11. Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study. Hutchison AJ, Maes B, Vanwalleghem J, Asmus G, Mohamed E, Schmieder R, Backs W, Jamar R, Vosskuhler A, Nephron Clin Pract 2006 102 2 61 71 10.1159/000088932 16224198 (Pubitemid 43087563)
12. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Joy MS, Finn WF, Am J Kidney Dis 2003 42 1 96 107 10.1016/S0272-6386(03)00554-7 12830461 (Pubitemid 36807658)
13. Relative in vitro efficacy of the phosphate binders lanthanum carbonate and sevelamer hydrochloride. Autissier V, Damment SJP, Henderson RA, J Pharm Sci 2007 96 2818 2827 10.1002/jps.20956 17497733 (Pubitemid 47597830)
14. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Chiu YW, Teitelbaum I, Misra M, de Leon EM, Adzize T, Mehrotra R, Clin J Am Soc Nephrol 2009 4 1089 1096 10.2215/CJN.00290109 19423571
15. Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study. Mehrotra R, Martin KJ, Fishbane S, Sprague SM, Zeig S, Anger M, Clin J Am Soc Nephrol 2008 3 5 1437 1445 10.2215/CJN.04741107 18579668
16. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. D'Haese PC, Spasovski GB, Sikole A, Hutchison A, Freemont TJ, Sulkova S, Swanepoel C, Pejanovic S, Djukanovic L, Balducci A, et al. Kidney Int Suppl 2003 63 suppl 85 73 78
17. Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. Finn WF, Joy MS, Hladik G, Clin Nephrol 2004 62 3 193 201 15481851 (Pubitemid 39236623)
18. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Hutchison AJ, Maes B, Vanwalleghem J, Asmus G, Mohamed E, Schmeider R, Backs W, Jamar R, Vosskuhler A, Nephron Clin Pract 2005 100 1 8 19 10.1159/000084653 (Pubitemid 40674602)